Open AccessUse of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers
Author(s) -
Scott Kopetz,
Kenna Shaw,
John Lee,
Jiexin Zhang,
Beate Litzenburger,
Vijaykumar Holla,
Walter Kinyua,
Emily Broaddus,
Molly S. Daniels,
Funda MericBernstam,
Russell R. Broaddus
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00213
Subject(s) - medicine , oncology , exome sequencing , exome , bioinformatics , proportional hazards model , gene , computational biology , biology , genetics , mutation
Smaller hotspot-based next-generation sequencing (NGS) panels have emerged to support standard of care therapy for patients with cancer. When standard treatments fail, it is unknown whether additional testing using an expanded panel of genes provides any benefit. The purpose of this study was to determine if larger sequencing panels that capture additional actionable genes, coupled with decision support, translates into treatment with matched therapy after frontline therapy has failed.